3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with amantadine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T; Yamamoto, I | 1 |
1 other study(ies) available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and amantadine
Article | Year |
---|---|
Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: 2-Amino-5-phosphonovalerate; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amantadine; Amino Acids; Animals; Anticonvulsants; Catalepsy; Dizocilpine Maleate; Dopamine Agonists; Dose-Response Relationship, Drug; Dronabinol; Drug Synergism; Ergolines; Haloperidol; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperazines; Quinpirole; Receptors, N-Methyl-D-Aspartate; Scopolamine | 1994 |